TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00598637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (Endeavor Resolute)
Description: stent is implanted due to randomization
Study: NCT04501107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of BioChaperone insulin lispro reconstituted with Humalog® (IMP1)
Description: Administration of IMP1 during a 12-hour euglycaemic clamp.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Ready-to-use BioChaperone insulin lispro (IMP2)
Description: Administration of IMP2 during a 12-hour euglycaemic clamp.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of US-approved Humalog® (IMP3)
Description: Administration of IMP3 during a 12-hour euglycaemic clamp.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of EU-approved Humalog® (IMP4)
Description: Administration of IMP4 during a 12-hour euglycaemic clamp.
Study: NCT00788047

Intervention type: DRUG
Group type: OTHER
Intervention: Dextromethorphan
Description: Dextromethorphan HCl 30 syrup single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon + Dextromethorphan
Description: Dimebon 20 mg tablets given three times daily for 14 days plus Dextromethorphan HCl 30 syrup single dose administered on Day 12
Study: NCT03341754

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D/ChAd63-CA
Description: Priming Component (DNA) = NMRC-M3V-D-PfCA (D-CA) Vaccine Boosting Component = ChAd63-PfCA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D/ChAd63-CAT
Description: Priming Component (DNA) = NMRC-M3V-D-PfCAT (D-CAT) Boosting Component = ChAd63-PfCAT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infectivity Control (IC) Group
Description: Subjects will be exposed to bites of 5 Anopheles stephensi mosquitoes carrying infectious Pf sporozoites within a controlled clinical environment.
Study: NCT01961804

Intervention type: DRUG
Group type: OTHER
Intervention: Reversion
Description: Administration of prothrombin complex concentrates: KANOKAD before CT Scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reversion
Description: Administration of prothrombin complex concentrates: KANOKAD before CT Scan
Study: NCT01072396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: double blind randomized crossover

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inhalation powder capsule identical to those containing tiotropium bromide inhalation powder
Study: NCT00327769

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg tablet
Study: NCT00070811

Intervention type: PROCEDURE
Intervention: Lip revision surgery
Description: Full or partial muscle thickness lip revision surgery.
Study: NCT04410289

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Airway positioning per specified protocol followed by Direct Laryngoscopy and Endotracheal Intubation
Description: Positioning of the patient's head and neck for the purpose of direct laryngoscopy and endotracheal intubation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Airway positioning per provider preference followed by Direct Laryngoscopy and Endotracheal Intubation
Description: Positioning of the patient's head and neck for the purpose of direct laryngoscopy and endotracheal intubation
Study: NCT03458767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eight weekly 90-minute group educational sessions
Description: Eight weekly 90-minute group educational sessions, originally developed for the MAPSS-MS intervention, adapted for remote web-based delivery.
Study: NCT04409067

Intervention type: DIAGNOSTIC_TEST
Intervention: electromyography
Description: Surface electromyography (sEMG) was used as an additional non-invasive tool for assessing patients with TMD.The electromyographical (EMG) potentials of the temporalis and masseter muscles were measured with a DAB-Bluetooth Instrument (Zebris Medical GmbH, Germany) at rest and during maximum voluntary clenching (MVC).

Intervention type: DIAGNOSTIC_TEST
Intervention: electromyography
Description: Surface electromyography (sEMG) was used as an additional non-invasive tool for assessing patients with TMD.The electromyographical (EMG) potentials of the temporalis and masseter muscles were measured with a DAB-Bluetooth Instrument (Zebris Medical GmbH, Germany) at rest and during maximum voluntary clenching (MVC).

Intervention type: DIAGNOSTIC_TEST
Intervention: electromyography
Description: Surface electromyography (sEMG) was used as an additional non-invasive tool for assessing patients with TMD.The electromyographical (EMG) potentials of the temporalis and masseter muscles were measured with a DAB-Bluetooth Instrument (Zebris Medical GmbH, Germany) at rest and during maximum voluntary clenching (MVC).
Study: NCT04287946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Ablation of a single-side of the greater splanchnic nerve
Study: NCT00522106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral graded activity
Description: The intervention is directed at increasing the level of activities in a time-contingent way, with the goal to integrate these activities in the daily living of the patients. The intervention is performed by physical therapists in primary care, on individual basis. Treatment period of maximal 12 weeks (with maximal 18 sessions), followed by 5 pre-set boostermoments with a maximum of 7 sessions (respectively in week 18, 25, 34, 42, and 55).
Study: NCT03642860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: Daily treatment with Triheptanoin oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oil
Description: Daily treatment with Safflower oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).
Study: NCT00522106

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: Treatment according to the Dutch physiotherapy guideline for patients with osteoarthritis of hip and/or knee. This guideline consists of general recommendations, emphasizing provision of information and advice, exercise therapy, and encouragement of a positive coping with the complaints. The treatment consisted of a maximum of 18 sessions within a period of 12 weeks. The treatment could be discontinued within the 12 week period if, according to the physiotherapists, all treatment goals were achieved.
Study: NCT03603145

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate insertion
Description: Immediate insertion of intrauterine contraception within 48 hours of medical abortion
Study: NCT03596723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPI-121 1%
Description: eye drops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate
Description: eye drops
Study: NCT01098500

Intervention type: DRUG
Intervention: Tyrosine kinase inhibitors
Description: Lapatinib, erlotinib, gefitinib, dasatinib, imatinib, nilotinib (analyzed as a class of drugs, not by individual drug)
Study: NCT04228146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Immediate access to the self-help CBT-I treatment, content of which is based on the translated Chinese version of a well-established CBT-I treatment manual entitled Insomnia: A Clinician's Guide to Assessment and Treatment. CBT-I aims at changing dysfunctional cognitive beliefs and maladaptive behaviors that contribute to the maintenance of insomnia. The self-help CBT-I treatment is delivered in Chinese language in six consecutive weekly modules via a smartphone application known as proACT-S. Duration of each module is around 45 to 60 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control
Description: Delay access to the self-help CBT-I treatment.
Study: NCT02198716

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous Coronary Intervention using drug eluting stents
Description: Percutaneous Coronary Intervention using drug eluting stents

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous Coronary Intervention using bare metal stents
Description: Percutaneous Coronary Intervention using bare metal stents
Study: NCT04086576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcohoot
Description: Alcohoot branded smartphone-paired breathalyzer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BACtrack Mobile Pro
Description: BACtrack Mobile Pro branded smartphone-paired breathalyzer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRIVESAFE Evoc
Description: DRIVESAFE Evoc branded smartphone-paired breathalyzer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BACtrack Vio
Description: BACtrack Vio branded smartphone-paired breathalyzer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drinkmate
Description: Drinkmate branded smartphone-paired breathalyzer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Floome
Description: Floome branded smartphone-paired breathalyzer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intoxilyzer 240
Description: Intoxilyzer 240 police grade breathalyzer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intoxilyzer 240
Description: Intoxilyzer 240 police grade breathalyzer
Study: NCT04043962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based CBT (Web-MAP)
Description: see arm description
Study: NCT00377780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non pegylated liposomal doxorubicin, trastuzumab, docetaxel
Description: max. 6 courses
Study: NCT02125448

Intervention type: DEVICE
Intervention: MRI and PET-CT
Study: NCT03482505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00004
Description: The INVSENSOR00004 will be placed on the subject's neck or chest to provide acoustic respiration rate.
Study: NCT03280771

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hope Soap
Description: HOPE SOAP© is a colourful, translucent bar of soap with a toy embedded in its centre.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Control group soap
Description: A colourful, translucent bar or soap with the toy alongside it
Study: NCT01394874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TLC
Description: Computer-based telephone linked communication will be used to counsel subjects to adhere to their exercise program over time.
Study: NCT03017326

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Arms A and B - cisplatin is used alone Arms C, D, E and F - cisplatin us used in combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Arms A and B - cisplatin is used alone Arms C, D, E and F - cisplatin us used in combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Arms A and B - cisplatin is used alone Arms C, D, E and F - cisplatin us used in combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Arms A and B - cisplatin is used alone Arms C, D, E and F - cisplatin us used in combination

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Arms A and B - cisplatin is used alone Arms C, D, E and F - cisplatin us used in combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Arms A and B - cisplatin is used alone Arms C, D, E and F - cisplatin us used in combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Arms C, D and E used in combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Arms C, D and E used in combination

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Arms C, D and E used in combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Arms C, D and E used in combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Arms C and D used in combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Arms C and D used in combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5Fluorouracil
Description: Arm C used alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Arms C and D used in combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Arms C and D used in combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Arm D used in combination
Study: NCT05484440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological
Study: NCT03922217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful My Way
Description: Mindful My Way (MMW) is a mobile application created for iOS, designed to delivered a form of mindfulness-based therapy to depressed older adults
Study: NCT00729157

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ziv-Aflibercept
Description: Given IV
Study: NCT03589326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Ponatinib Tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Imatinib Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine IV injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone Tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Cytarabine IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate IV infusion.
Study: NCT03017326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Arm D used in combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Arm F used in combination
Study: NCT03589326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone Tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone Tablets.
Study: NCT04500483

Intervention type: DIAGNOSTIC_TEST
Intervention: indirect calorimetry
Description: measurement of resting energy expenditure using indirect calorimetry

Intervention type: DIAGNOSTIC_TEST
Intervention: indirect calorimetry
Description: measurement of resting energy expenditure using indirect calorimetry
Study: NCT01177293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine - reference
Description: Amlodipine capsule, 10 mg, single dose, with water
Study: NCT03017326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Arm F used in combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Arm used in combination
Study: NCT02020239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT00746096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IKH-01
Description: ethinyl estradiol 0.035mg and norethisterone 1mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for ethinyl estradiol 0.035mg and norethisterone 1mg
Study: NCT02378740

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion
Study: NCT02980926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Description: This is a shorter acting spinal anesthetic as compared to the current standard of care at this institution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: This is the current standard of care at this institution and many centers. This is a longer acting spinal anesthetic compared to the study drug.
Study: NCT04387864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body Vibration Device
Description: Power Plate® (pro5TM; Power Plate North America, Inc., Northbrook, IL, USA)
Study: NCT02597465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1507
Description: The administered dose is calculated based on the BSA calculated for the subject on Day 1 of the Cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference1507
Description: Investigators choice including chemotherapy or supportive therapy
Study: NCT03728608

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Feeding tube dwell time of 48 hours
Description: Feeding tube dwell time of 48 hours for first 4 weeks of life.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Feeding tube dwell time of 7 day
Description: Feeding tube dwell time of 7 days for first 4 weeks of life.
Study: NCT00978484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy - Dynamic
Description: 10 weeks of Virtual Reality Exposure using full, immersive VR

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Augmented Exposure Therapy
Description: Exposure Therapy augmented with a still computer image
Study: NCT01099514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: D1\~ Nilotinib 400 mg (2 capsules) PO BID q 28 days
Study: NCT03198286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive treatment summary and survivor care plan
Study: NCT00953303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucocorticoid
Description: One dose of Dexamethasone (20mg/day) followed by prednisone 1mg/kg/day with a maximum dose of 60mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: The patients will be given standard care such as diuretics, inotropic and/or vasodilator in acute decompensated congestive heart failure management.
Study: NCT03056625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin A fortified rice
Description: Lactating women will receive fortified rice one meal per day on weekdays for a period of 14 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal rice
Description: Lactating women will receive normal rice one meal per day on weekdays for a period of 14 weeks.
Study: NCT02613221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab + TAS-102
Description: panitumumab + TAS-102 combination therapy
Study: NCT01465607

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mujer Segura
Description: Brief (35-minute) counseling intervention using techniques from Motivational Interviewing and principles of social cognitive theory (SCT) and theory of reasoned action (TRA).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CENSIDA counseling program
Description: Didactic HIV and STI counseling involving some personal risk assessment and presenting appropriate information on methods of transmission and for avoiding or reducing the risk of infection. Based on a counseling manual disseminated by CENSIDA, Mexico's federal HIV-AIDS prevention agency.
Study: NCT01194895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protective ventilation
Description: set tidal volume of 5ml/kg during one-lung ventilation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional ventilation
Description: keep tidal volume at 8ml/kg during one-lung ventilation
Study: NCT01177293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine ODT - test
Description: Amlodipine orally disintegrating tablet (ODT), 10 mg, single dose, without water
Study: NCT03343704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarucizumab
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarucizumab
Description: Intravenous
Study: NCT01868438

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyronaridine-artesunate granules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyronaridine-artesunate granules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyronaridine-artesunate tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyronaridine-artesunate tablets
Study: NCT03202940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib is an oral ALK inhibitor. The term ALK inhibitor means that alectinib targets the abnormal ALK protein that is causing lung cancer cells to grow

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib is an oral inhibitor of MEK, a signaling protein that can cause some types of lung cancer to grow
Study: NCT01322789

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous Mesenchymal stem cell infusion
Description: Four consecutive intravenous infusions 1 week apart followed by 4 consecutive infusions 1 month apart